‘De-extinction’ startup Colossal Biosciences makes its first acquisition: a company that clones pets

Core Insights - The cloning industry is experiencing contraction, highlighted by Colossal Biosciences' acquisition of ViaGen Pets and Equine, marking its first acquisition since its inception in 2021 [1][4] Company Overview - Colossal Biosciences, based in Texas, is recognized for its controversial de-extinction projects aimed at recovering extinct species, including a claim of having "brought back" dire wolves through DNA modification [2] - The company has garnered significant interest from investors, raising $120 million to pursue the resurrection of the dodo, enhancing its genetic capabilities with the acquisition of ViaGen [3] Acquisition Details - ViaGen, established in 2002, will maintain its leadership and focus on expanding its cloning activities for endangered species post-acquisition [5] - The acquisition grants Colossal access to ViaGen's exclusive licensing of breakthrough technologies from the Roslin Institute, known for cloning Dolly the sheep, the first cloned mammal [5] Strategic Implications - The partnership with ViaGen is seen as a significant opportunity for Colossal to leverage advanced cloning and cryopreservation techniques to further its de-extinction and species restoration goals [6]